Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.14309/AJG.0000000000001596 | ||||
| Año | 2022 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
INTRODUCTION: Several scoring systems predict mortality in alcohol-associated hepatitis (AH), including the Maddrey discriminant function (mDF) and model for end-stage liver disease (MELD) score developed in the United States, Glasgow alcoholic hepatitis score in the United Kingdom, and age, bilirubin, international normalized ratio, and creatinine score in Spain. To date, no global studies have examined the utility of these scores, nor has the MELD-sodium been evaluated for outcome prediction in AH. In this study, we assessed the accuracy of different scores to predict short-term mortality in AH and investigated additional factors to improve mortality prediction. METHODS: Patients admitted to hospital with a definite or probable AH were recruited by 85 tertiary centers in 11 countries and across 3 continents. Baseline demographic and laboratory variables were obtained. The primary outcome was all-cause mortality at 28 and 90 days. RESULTS: In total, 3,101 patients were eligible for inclusion. After exclusions (n = 520), 2,581 patients were enrolled (74.4% male, median age 48 years, interquartile range 40.9-55.0 years). The median MELD score was 23.5 (interquartile range 20.5-27.8). Mortality at 28 and 90 days was 20% and 30.9%, respectively. The area under the receiver operating characteristic curve for 28-day mortality ranged from 0.776 for MELD-sodium to 0.701 for mDF, and for 90-day mortality, it ranged from 0.773 for MELD to 0.709 for mDF. The area under the receiver operating characteristic curve for mDF to predict death was significantly lower than all other scores. Age added to MELD obtained only a small improvement of AUC. DISCUSSION: These results suggest that the mDF score should no longer be used to assess AH's prognosis. The MELD score has the best performance in predicting short-term mortality.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Morales-Arraez, Dalia | Mujer |
Univ Pittsburgh - Estados Unidos
Hosp Univ Canarias - España University of Pittsburgh Medical Center - Estados Unidos Hospital Universitario de Canarias - España |
| 2 | Ventura-Cots, Meritxell | - |
Univ Pittsburgh - Estados Unidos
University of Pittsburgh Medical Center - Estados Unidos |
| 3 | Altamirano, José | Hombre |
Hosp Quironsalud - España
Hospital Quirónsalud - España |
| 4 | Abraldes, Juan G. | Hombre |
Univ Alberta - Canadá
University of Alberta - Canadá |
| 5 | Cruz-Lemini, M. | Mujer |
St Pau Univ Hosp - España
Inst Salud Carlos III - España Sant Pau University Hospital - España Instituto de Salud Carlos III - España |
| 6 | Thursz, Mark Richard | Hombre |
Imperial Coll London - Reino Unido
Imperial College London - Reino Unido |
| 7 | Atkinson, S. R. | Hombre |
Univ Pittsburgh - Estados Unidos
Imperial Coll London - Reino Unido University of Pittsburgh Medical Center - Estados Unidos Imperial College London - Reino Unido |
| 8 | Sarin, Shiv Kumar | Hombre |
Inst Liver & Biliary Sci - India
Institute of Liver and Biliary Sciences - India |
| 9 | Kim, W. H. | - |
Seoul Natl Univ - Corea del Sur
Seoul Metropolitan Government - Seoul National University Borame Medical Center - Corea del Sur |
| 10 | Araujo, Roberta C. | Mujer |
UNIV SAO PAULO - Brasil
Universidade de São Paulo - Brasil |
| 11 | de la Tijera, M. F. | - |
Hosp Gen Mexico City - México
|
| 11 | Higuera-de La Tijera, M. F. | - |
Hosp Gen Mexico City - México
|
| 11 | Higuera-de-la-Tijera, Fatima | Mujer |
Hosp Gen Mexico City - México
Hospital General de México - México |
| 12 | Singal, Ashwani K. | - |
Univ Alabama Birmingham - Estados Unidos
The University of Alabama at Birmingham - Estados Unidos UAB Division of Gastroenterology & Hepatology - Estados Unidos |
| 13 | Shah, Vijay H. | Hombre |
Mayo Clin - Estados Unidos
Mayo Clinic - Estados Unidos |
| 14 | Kamath, P. S. | Hombre |
Mayo Clin - Estados Unidos
Mayo Clinic - Estados Unidos |
| 15 | Duarte-Rojo, A. | - |
Univ Arkansas Med Sci - Estados Unidos
University of Arkansas for Medical Sciences - Estados Unidos UAMS College of Medicine - Estados Unidos |
| 16 | Charles, E. A. | - |
Univ Pittsburgh - Estados Unidos
University of Pittsburgh Medical Center - Estados Unidos |
| 17 | Vargas, Victor | Hombre |
UNIV AUTONOMA BARCELONA - España
CIBERehd - España Hospital Universitari Vall d'Hebron - España |
| 18 | Jager, M. | - |
Hop Beaujon - Francia
Hôpital Beaujon - Francia |
| 19 | Rautou, Pierre Emmanuel | Hombre |
Hop Beaujon - Francia
PARCC - Francia Hôpital Beaujon - Francia PARCC - Paris-Centre de Recherche Cardiovasculaire - Francia |
| 20 | Rincón, Diego | Hombre |
Hosp Gen Univ Gregorio Maranon - España
UNIV COMPLUTENSE - España Hospital General Universitario Gregorio Marañón - España CIBERehd - España |
| 21 | Zamarripa, Felipe | Hombre |
Juarez Hosp - México
Juarez Hospital - México |
| 22 | Restrepo, Juan Carlos | Hombre |
UNIV ANTIOQUIA - Colombia
Universidad de Antioquia - Colombia |
| 23 | Torre, Aldo | Hombre |
Inst Nacl Ciencias Med & Nutr Salvador Zubiran - México
Instituto Nacional de la Nutrición Salvador Zubiran - México |
| 24 | Lucey, M. R. | Hombre |
UNIV WISCONSIN - Estados Unidos
University of Wisconsin School of Medicine and Public Health - Estados Unidos |
| 25 | Arab, Juanpablo | Hombre |
Pontificia Universidad Católica de Chile - Chile
Escuela de Medicina - Chile |
| 25 | Arab, J. P. | - |
Pontificia Universidad Católica de Chile - Chile
|
| 26 | Mathurin, Philippe | Hombre |
CHU Lille - Francia
Univ Lille - Francia Université de Lille - Francia Institute for Translational Research in Inflammation (INFINITE) - Francia |
| 27 | Louvet, Alexandre | Hombre |
CHU Lille - Francia
|
| 28 | Garcia-Tsao, G. | Mujer |
YALE UNIV - Estados Unidos
VA CT Healthcare Syst - Estados Unidos Yale School of Medicine - Estados Unidos |
| 28 | Garcia-Tsao, G. | - |
YALE UNIV - Estados Unidos
VA CT Healthcare Syst - Estados Unidos |
| 29 | Gonzalez, J. A. | Hombre |
Univ Autonoma Nuevo Leon - México
Hospital Universitario Dr. Jose Eleuterio Gonzalez - México |
| 30 | Verna, Elizabeth | Mujer |
Columbia Univ Irving Med Ctr - Estados Unidos
Columbia University Irving Medical Center - Estados Unidos Columbia Univ - Estados Unidos |
| 31 | Brown, Robert S. | Hombre |
Weill Cornell Med Coll - Estados Unidos
Weill Cornell Medicine - Estados Unidos |
| 32 | Argemi, Josepmaria | - |
Univ Pittsburgh - Estados Unidos
Clin Univ Navarra - España University of Pittsburgh Medical Center - Estados Unidos Universidad de Navarra - España Clínica Universidad de navarra - España |
| 33 | Fernandez-Carrillo, Carlos | - |
Univ Pittsburgh - Estados Unidos
University of Pittsburgh Medical Center - Estados Unidos |
| 33 | Fernandez-Carrillo, Carlos | Hombre |
Univ Pittsburgh - Estados Unidos
|
| 34 | Clemente-Sanchez, Ana | - |
Univ Pittsburgh - Estados Unidos
HGU Gregorio Maranon - España Inst Salud Carlos III - España University of Pittsburgh Medical Center - Estados Unidos Hospital General Universitario Gregorio Marañón - España Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas - España CIBERehd - España Instituto de Salud Carlos III - España |
| 35 | Alvarado-Tapias, Edilmar | - |
Univ Pittsburgh - Estados Unidos
University of Pittsburgh Medical Center - Estados Unidos |
| 36 | Forrest, E. | Hombre |
Glasgow Royal Infirm - Reino Unido
Glasgow Royal Infirmary - Reino Unido |
| 37 | Allison, M. | - |
Cambridge Biomed Res Ctr - Reino Unido
Cambridge Biomedical Research Centre - Reino Unido |
| 38 | Avila, Matias A. | Hombre |
Univ Pittsburgh - Estados Unidos
University of Pittsburgh Medical Center - Estados Unidos |
| 38 | Bataller, R. | - |
Univ Pittsburgh - Estados Unidos
|
| 38 | Bataller, R. | - |
Univ Pittsburgh - Estados Unidos
|
| Fuente |
|---|
| Instituto de Salud Carlos III |
| Chilean government through the Fondo Nacional de Desarrollo Cientifico y Tecnologico |
| National Institute on Alcohol Abuse and Alcoholism |
| NIAAA |
| National Institute of Diabetes and Digestive and Kidney Diseases |
| Comision Nacional de Investigaci'on Cientifica y Tecnologica (CONICYT, CARE Chile UC) |
| Spanish Association for the Study of the Liver (AEEH) |
| Instituto de Salud Carlos III-Spanish Ministry of Health |
| Agradecimiento |
|---|
| R.B. is a recipient of NIAAA U01AA021908 and U01AA020821. D.M.A., M.V.C., J.A., C.F.C., and A.C. are recipients of a scholarship grant for study extension abroad, sponsored by the Spanish Association for the Study of the Liver (AEEH). M.V.C. is a recipient of the Juan Rodes grant from Instituto de Salud Carlos III. During the conduct of the study, A.K.S. is funded by the NIAAA 1R21AA02327301A1 grant. Juan Pablo Arab receives support from the Chilean government through the Fondo Nacional de Desarrollo Cientifico y Tecnol ' ogico (FONDECYT 1200227) and the Comisi ' on Nacional de Investigaci ' on Cientifica y Tecnol ' ogica (CONICYT, AFB170005, CARE Chile UC). M.C.L. is supported by Juan Rod ' es contract JR19/00047, Instituto de Salud Carlos III-Spanish Ministry of Health." |
| R.B. is a recipient of NIAAA U01AA021908 and U01AA020821. D.M.A., M.V.C., J.A., C.F.C., and A.C. are recipients of a scholarship grant for study extension abroad, sponsored by the Spanish Association for the Study of the Liver (AEEH). M.V.C. is a recipient of the Juan Rodes grant from Instituto de Salud Carlos III. During the conduct of the study, A.K.S. is funded by the NIAAA 1R21AA023273-01A1 grant. Juan Pablo Arab receives support from the Chilean government through the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT 1200227) and the Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT, AFB170005, CARE Chile UC). M.C.L. is supported by Juan Rodes contract JR19/00047, Instituto de Salud Carlos III-Spanish Ministry of Health." |
| R.B. is a recipient of NIAAA U01AA021908 and U01AA020821. D.M.A., M.V.C., J.A., C.F.C., and A.C. are recipients of a scholarship grant for study extension abroad, sponsored by the Spanish Association for the Study of the Liver (AEEH). M.V.C. is a recipient of the Juan Rodes grant from Instituto de Salud Carlos III. During the conduct of the study, A.K.S. is funded by the NIAAA 1R21AA02327301A1 grant. Juan Pablo Arab receives support from the Chilean government through the Fondo Nacional de Desarrollo Cientifico y Tecnol ' ogico (FONDECYT 1200227) and the Comisi ' on Nacional de Investigaci ' on Cientifica y Tecnol ' ogica (CONICYT, AFB170005, CARE Chile UC). M.C.L. is supported by Juan Rod ' es contract JR19/00047, Instituto de Salud Carlos III-Spanish Ministry of Health." |